ALSO APPROVED FOR CHILDREN 6-11 YEARS OLD WITH MODERATE TO SEVERE PLAQUE PSORIASIS
In a clinical study at 12 weeks, nearly 7 out of 10 adolescent patients (ages 12-17) with moderate to severe plaque psoriasis were rated as cleared or minimal and 8 out of 10 saw at least 75% clearer skin. Individual results may vary. Clearer skin was assessed based on an evaluation of a patient’s entire body, including the head, upper limbs, trunk, and lower limbs.
Approved for Children 6 and Up with Moderate to Severe Plaque Psoriasis
Help Your Youngster With Plaque Psoriasis
Childhood and adolescence are both exciting but occasionally difficult times. If your child is suffering from moderate to severe plaque psoriasis, however, things may be more difficult than exciting. Symptoms like red or scaling plaques on the skin can make things tough for your youngster.
Results With STELARA®
SKIN CLEARANCE AT WEEK 12 FOR ADOLESCENTS AGES 12-17
In a clinical study, most patients 12-17 years of age with moderate to severe plaque psoriasis were rated cleared or minimal at week 12.
STELARA® is also approved for pediatric patients ages 6-11.
The safety and effectiveness of STELARA® has been established in both adolescent and pediatric* patients.
*Pediatric patients knew they were on STELARA® for the entire study.
Talk with your child’s dermatologist to decide if STELARA® may be the right treatment.
STELARA® isn’t right for everyone. Individual results may vary.
STELARA®: A History of Plaque Psoriasis Treatment
*Approved for the treatment of adult patients with moderate to severe plaque psoriasis in September 2009.
†This is based on information licensed from IQVIA: LAAD claims, NPA, DDD for the period 2009-2020 reflecting estimates of real-world activity and based on custom methodologies developed by Janssen. All rights reserved.
Fewer Doses Per Year
Help your child stay on treatment. STELARA® is given just 4 times a year every 12 weeks, after 2 starter doses at weeks 0 and 4. STELARA® is given as an injection under the skin. For children 6 years of age and older, it is recommended that STELARA® be given by a healthcare provider.
FIRST 52 WEEKS OF TREATMENT
STELARA®(ustekinumab)
6Injections
Once every 12 weeks (after 2 starter doses at weeks 0 and 4)
STELARA® is a prescription medicine used to treat adults and children 6 years and older with moderate or severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
Blocks IL-12 and IL-23 proteins involved in inflammatory immune responses
Enbrel®‡§(etanercept)
52Injections
Once every week
Enbrel® is a prescription medicine used to treat chronic moderate to severe plaque psoriasis in children 4 years and older and adults who may benefit from taking injections or pills (systemic therapy) or phototherapy (ultraviolet light).
Blocks TNF-alpha & TNF-beta proteins involved in inflammatory and immune responses
Taltz®§||(ixekizumab)
12Doses
Once every 4 weeks (after 1 starter dose at week 0)
In pediatric patients greater than 50 kg, 2 80-mg injections are to be administered at week 0.
Taltz® is a prescription medicine used to treat people 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light).
Blocks IL-17A proteins involved in inflammatory and immune responses
‡Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
§Indicated trademarks are registered trademarks of their respective owners.
||Taltz® is indicated for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
While frequency of treatment matters, there are other important factors to consider. Ask a dermatologist if STELARA® is right for your child. The above chart is not intended to compare the safety and effectiveness of these treatments. Please refer to each product’s full Prescribing Information for recommended dosing and administration.
Download our brochure to learn more about STELARA® for children 6 years and older with moderate or severe plaque psoriasis.
What is STELARA®?
STELARA® is the only biologic that blocks both the IL-12 and IL-23 proteins, which are part of the immune system, and are thought to play a role in plaque psoriasis. Click here to find out more about how STELARA® works.
